What's new

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 17, Status: Authorised

Jun 19, 2025 - 12:25
 0
Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 17, Status: Authorised
Read More

Tags:

Previous Article

STAT+: What’s next for Sarepta Therapeutics with gene therapy under fire?

Next Article

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab...

Related Posts

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt Treatment of cutaneous T-cell lymphoma, 13/04/2021 Withdrawn

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene...

Jun 10, 2025  0

Annex to 27-30 January 2025 CHMP Minutes

May 28, 2025  0

Human medicines European public assessment report (EPAR): Nerlynx, neratinib, Date of authorisation: 31/08/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0